Characteristics of long-term DAPT group and short-term DAPT group
| Number of patients | Long-term DAPT (n=65) | Short-term DAPT (n=71) | P value |
| Age: mean±SD | 58.9±12.3 | 59.2±12.8 | 0.934 |
| Man: n (%) | 15 (23.1) | 26 (36.6) | 0.086 |
| Previous SAH | 3 (4.6) | 6 (8.5) | 0.369 |
| Previous hemorrhagic stroke | 0 (0.0) | 1 (1.4) | 0.337 |
| Previous ischemic stroke | 2 (3.1) | 1 (1.4) | 0.508 |
| Risk factors: n (%) | |||
| Hypertension | 31 (47.7) | 29 (40.8) | 0.422 |
| Diabetes | 6 (9.2) | 2 (2.8) | 0.112 |
| Dyslipidemia | 25 (38.5) | 20 (28.2) | 0.203 |
| Smoking habit | 13 (20.0) | 12 (16.9) | 0.641 |
| Target aneurysm, symptoms: n (%) | 0.118 | ||
| Asymptomatic | 64 (98.5) | 66 (93.0) | |
| Symptomatic | 1 (1.5) | 5 (7.0) | |
| Target aneurysm, locations: n (%)* | |||
| ICA-cavernous | 0 (0.0) | 1 (1.4) | |
| ICA-paraclinoid | 32 (49.2) | 29 (40.8) | |
| ICA-PcomA | 6 (9.2) | 9 (12.7) | |
| ICA-bifurcation | 1 (1.5) | 1 (1.4) | |
| MCA-bifurcation | 2 (3.1) | 4 (5.6) | |
| AcomA | 5 (7.7) | 7 (9.9) | |
| VA | 9 (13.8) | 10 (14.1) | |
| VA-PICA | 2 (3.1) | 2 (2.8) | |
| BA trunk | 1 (1.5) | 0 (0.0) | |
| BA-SCA | 1 (1.5) | 0 (0.0) | |
| BA bifurcation | 7 (10.8) | 7 (9.9) | |
| PCA | 0 (0.0) | 1 (1.4) | |
| Others (anterior circulation) | 1 (1.5) | 1 (1.4) | |
| Target aneurysm, maximum diameter (mm): mean±SD | 6.97±2.84 | 7.06±2.42 | 0.494 |
| Target aneurysm, maximum diameter <10 mm: n (%) | 56 (86.2) | 61 (85.9) | 0.968 |
| Target aneurysm, subtype: n (%) | 0.713 | ||
| Saccular | 54 (83.1) | 55 (77.5) | |
| Fusiform | 7 (10.8) | 10 (14.1) | |
| Dissecting | 4 (6.2) | 6 (8.5) | |
| Patients with aneurysm not eligible for inclusion to this trial: n (%) | 14 (21.5) | 10 (14.1) | 0.255 |
| Radiographic outcome: n (%) | 0.103 | ||
| Complete occlusion | 28 (43.1) | 21 (29.6) | |
| Neck remnant | 24 (36.9) | 25 (35.2) | |
| Aneurysm filling | 13 (20.0) | 25 (35.2) | |
| Deployed stent: n (%) | 0.836 | ||
| Enterprise VRD | 3 (4.6) | 0 (0.0) | |
| Enterprise 2 | 8 (12.3) | 11 (15.5) | |
| Neuroform EZ | 5 (7.7) | 4 (5.6) | |
| Neuroform Atlas | 19 (29.2) | 19 (26.8) | |
| LVIS | 21 (32.3) | 28 (39.4) | |
| LVIS Jr | 7 (10.8) | 7 (9.9) | |
| Double stents† | 2 (3.1) | 2 (2.8) | |
| Pre-procedural ARU: mean±SD | 444.6±66.3 (n=55) | 445.0±83.7 (n=55) | 0.779 |
| Pre-procedural PRU: mean±SD | 161.2±75.6 (n=55) | 170.7±78.3 (n=55) | 0.473 |
*Target aneurysm, location includes the cases with multiple aneurysm (duplicated aggregation).
†Details of double stents: One case was treated with 2 Neuroform Atlas and the other case was treated with 2 LVIS in long-term DAPT group. One case was treated with 2 LVIS Jr and the other case was treated with Enterprise VRD and Neuroform Atlas in short-term DAPT group.
AcomA, anterior communicating artery; ARU, aspirin reaction units; BA, basilar artery; DAPT, dual antiplatelet therapy; ICA, internal carotid artery; LVIS, Low-profile Visualized Intraluminal Support; MCA, middle cerebral artery; PCA, posterior cerebral artery; PcomA, posterior communicating artery; PICA, posterior inferior cerebellar artery; PRU, P2Y12 reaction units; SAH, subarachnoid hemorrhage; SCA, superior cerebellar artery; VA, vertebral artery.